2014

Qualia Clinical Services Announces the Opening of Its Omaha, NE Facility

    OMAHA, Neb., Sept. 12 /PRNewswire/ -- Qualia Clinical Services, a
 contract research organization (CRO), announces the opening of its 160-bed,
 23,000 sq ft clinical research facility in Omaha, Nebraska for the conduct
 of studies in healthy volunteers and special patient populations. The
 state-of- the-art facility includes a Phase I clinic (22 hospital beds),
 five bioavailability/bioequivalence dorms, separate participant recruitment
 area, onsite sample processing laboratory, treatment rooms, kitchen, dining
 room, physicians' offices, controlled-access pharmacy, wireless access
 through-out the facility and secured drug storage room along with
 administrative offices.
     Sohail Khattak, MD, FRCP(C) founded Qualia Clinical Services based on
 his extensive background as a Principal Investigator and manager of Phase
 I-IV clinical trials. Dr. Khattak serves on several scientific advisory
 boards of major pharmaceutical companies and has formed an impressive
 medical advisory board at Qualia. The medical advisory board is chaired by
 Mohammed Quader, M.D. and focuses on the quality of clinical research while
 providing the senior management team with access to the latest and most
 accurate medical information.
     "We have a strong foundation and are poised to be a global leader in
 the contract clinical research arena," said Sohail Khattak, MD, FRCP(C),
 president and CEO, Qualia. "The technologies of Qualia combined with our
 experience ensure the rapid implementation and completion of projects."
     The senior management team at Qualia (Omaha) combines over 75 years of
 experience in the CRO industry. Azhar Kalim serves as vice president,
 business development and general manager of North American clinical
 operations. He has over 16 years of experience in the CRO industry, serving
 in the vital oversight roles of strategic growth of the company and
 business development initiatives. Mark McDonald, executive director of
 operations, heads the clinical operations team. With over 15 years of phase
 I clinical research experience, his background includes extensive expertise
 in the organization of clinical operations and client relationship
 development. Jim Cunningham, director of recruiting, has been establishing
 successful recruitment operations in the Midwest for the past six years and
 is one of the best in the industry. Robert Schwab, MD, serves as principal
 investigator. Prior to joining Qualia, Dr. Schwab was the medical director
 for the ambulatory clinics of University of Nebraska Medical Center (UNMC)
 Physicians. He is board certified in internal medicine and has been named
 one of Omaha's top physicians from 2002-2005.
     The facility is staffed with a highly trained and dedicated contingent
 of clinical professionals having focused expertise in Phase I clinical
 research. Some of the top-ten pharmaceutical companies have performed
 audits of the facility and have been extremely impressed with breadth of
 experience of Qualia's staff and the state-of-the-art facility.
     "The opening of our clinical research facility in Omaha, combined with
 our world-class scientific expertise and exceptional customer care, marks
 our ability to be a unique partner to the pharmaceutical, generic and
 biotechnology industries," said Azhar Kalim, vice president and general
 manager. "Qualia is dedicated to redefining clinical research services in
 terms of quality -- applying strategic thought to each project,
 anticipating client needs, delivering accurate results -- and quantity,
 with a solid database of study participants readily available for clinical
 trials."
     Serving the pharmaceutical, biotechnology and generic industries,
 Qualia offers extensive expertise in early phase clinical research (Phase
 I-IIa) and late-phase clinical trials (Phase IIb-IV), clinical
 pharmacology, bioequivalence, PK/PD analysis, data management and
 statistical services. It's access to a large base of normal healthy
 participants and special populations ensures rapid study initiation and
 on-time completion. With facilities in Canada, United States and Europe,
 Qualia is redefining the clinical research industry in terms of quality --
 overall client experience, accurate data, rapid study start-up -- and
 quantity -- access to qualified study participants. Detailed information
 about the company is available at the Qualia site at www.qualiaclinical.com
 or by calling 1-866-629-7100.
     Certain statements in this press release constitute "forward-looking
 statements" within the meaning of the United States Securities Legislation.
 The Company's actual results could differ from those in the forward-looking
 statements. Do not construe this information as investment advice. This is
 not a solicitation to buy or sell securities. This does not purport to be a
 complete analysis of the Company. Investing in securities is speculative
 and carries a high degree of risk. Past performance does not guarantee
 future results. Readers should consult their own independent advisers with
 any investment, including any contemplated investment. All information
 contained in this press release should be independently investigated. This
 press release contains forward-looking statements. These remarks involve
 risks and uncertainties. Risks are not limited to quarterly fluctuations in
 results or the companies' management of growth and competition. Other risks
 are detailed in the Company's SEC filings. Actual results may differ
 materially from such information set forth herein.
     Contact:  Azhar Kalim
               Vice President, Business Development
               Qualia Clinical Services
               1-866-629-7100
               bd@qualiaclinical.com
 
 

SOURCE Qualia Clinical Services

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.